Sangamo Biosciences (SGMO) has disclosed a new risk, in the Manufacturing category. Sangamo Biosciences does not face any business risks ...

Key regulatory milestones and financial updates position Sangamo Therapeutics Inc (SGMO) for potential growth despite funding ...

Wells Fargo raised the firm’s price target on Sangamo (SGMO) to $3 from $1 and keeps an Equal Weight rating on the shares. The firm views ...

RBC Capital Mkts has recently reduced Sangamo Therapeutics Inc (SGMO) stock to Sector Perform rating, as announced on November 3, 2023, according to Finviz. Earlier, on April 28, 2023, BofA Securities ...

RICHMOND, Calif., November 12, 2024 -- ( BUSINESS WIRE )--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported business highlights and third quarter 2024 financial ...

Now Gilead is spending a further $150 million upfront to access the cutting edge gene-editing technology of another Californian biotech, Sangamo. The ambition for this cancer-focused collaboration ...

Sangamo Therapeutics (SGMO) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.34 per share a year ago.

On a per-share basis, the Richmond, California-based company said it had profit of 4 cents. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks ...

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Free Report) reached a new 52-week high on Wednesday after HC Wainwright raised their price target on the stock from $5.00 to $10.00. HC ...

Sangamo Therapeutics has a twelve month low of $0.29 and a twelve month high of $3.18. Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into ...

Sangamo Therapeutics SGMO is preparing to release its quarterly earnings on Tuesday, 2024-11-12. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect ...

Good afternoon and welcome to the Sangamo Therapeutics Third Quarter 2024 Teleconference Call. Please be advised that today's conference is being recorded. I would now like to turn the conference over ...